Areas of Expertise (10)
Healthcare Economics and Policy
Applications in Healthcare
Supply Chain Management
Professor Iacocca is adept at explaining the complexities of the U.S. healthcare economy and pharmaceutical drug pricing system in a way that provides clarity and understanding for her audience. Her research is focused primarily on the healthcare industry, with specific focus on supply chains and optimization. She also more generally completes research in operations and analytics.
Rutgers University: PhD
The University of Scranton: MBA
The University of Scranton: BS
Select Accomplishments (5)
Emerald Literati Network Award for Excellence (professional)
2016 Selected by the editors of the International Journal of Quality & Reliability Management for the paper “Improving the Quality of Environmental Management: Impact on Shareholder Value”
Awarded 2nd Place in the INFORMS Annual Case Competition (professional)
2015 Presented case at the INFORMS Annual Meeting in Philadelphia, PA.
Emerald Literati Network Award for Excellence
2014 Selected by the editors of the International Journal of Pharmaceutical and Healthcare Marketing for the paper “Resell versus direct models in brand drug distribution”
Highly Commendable Paper Award (professional)
2013 Selected by the editors of the International Journal of Pharmaceutical and Healthcare Marketing for the paper “Resell versus direct models in brand drug distribution”
Recipient of the “KSOM Professor of the Year” Award (professional)
2013 Determined by student vote
- Data Analytics, Statistics, and Operations Consultant, Fortune 50 Company
- Member, Institute for Operations Research and Management Science (INFORMS)
- Member, Decision Sciences Institute (DSI)
- Member, The Association for Operations Management (APICS)
Select Media Appearances (2)
GUEST VIEW: The healthcare industry is sick: But can it afford to get better?
American Pharmacy News online
Right now, President Trump and lawmakers in Washington are wrangling over the details of a proposed healthcare law that would “repeal and replace” Obamacare. Through all of the rhetoric and political jockeying, it’s important to remember that there is a huge industry in the middle of this fight. And that industry is in crisis.
Pharma seeks growth in eyecare
But where some see this as a cautionary tale, others see a potentially successful new idea poorly executed. “It’s a shame to think of this as a failure, because I do think a model like this could work,” says Kathleen Iacocca, PhD, an assistant professor at Villanova University School of Business, who has studied drug supply chains. “The issue was the insured. The company took a leap of faith without checking to make sure if insurance would actually pay. But imagine if a manufacturer could partner with a third party where pre-authorization could take place. That model would be groundbreaking.”
Select Academic Articles (5)
Why brand drugs priced higher than generic equivalentsInternational Journal of Pharmaceutical and Healthcare Marketing
Kathleen Iacocca, James Sawhill, Yao Zhao
The point of purchase decision in a supply chain with value-added resellingInternational Journal of Production Research
Kingsley Gnanendran and Kathleen Iacocca
Resell vs. Direct Models: US Branded Drug Distribution in the FuturePharmaceutical Executive
Iacocca, K., Zhao, Y.
Resell versus direct models in brand drug distributionInternational Journal of Pharmaceutical and Healthcare Marketing
Kathleen Iacocca, Yao Zhao, Adam Fein
A multiple regression model to explain the cost of brand-drugsSocio-Economic Planning Sciences
Kathleen Iacoccaa, JamesSawhill, YaoZhao